A Randomized, Double-blinded, Single-dose, 3-arms Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2306 Injection vs Secukinumab Injection (Cosentyx) in Healthy Chinese Male Subjects
Latest Information Update: 30 Aug 2023
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis
- Focus Pharmacokinetics
- Sponsors Bio-Thera Solutions
Most Recent Events
- 25 Aug 2023 Status changed from active, no longer recruiting to completed.
- 02 Jun 2023 Planned End Date changed from 4 May 2023 to 21 Sep 2023.
- 02 Jun 2023 Planned primary completion date changed from 4 May 2023 to 3 Jul 2023.